Caribou Biosciences, Inc. (CRBU)
NASDAQ: CRBU · Real-Time Price · USD
2.200
+0.050 (2.33%)
At close: Apr 17, 2026, 4:00 PM EDT
2.242
+0.042 (1.92%)
After-hours: Apr 17, 2026, 7:29 PM EDT
Caribou Biosciences Revenue
In the year 2025, Caribou Biosciences had annual revenue of $11.16M with 11.66% growth. Caribou Biosciences had revenue of $3.94M in the quarter ending December 31, 2025, with 89.74% growth.
Revenue (ttm)
$11.16M
Revenue Growth
+11.66%
P/S Ratio
19.05
Revenue / Employee
$115,041
Employees
97
Market Cap
212.60M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 11.16M | 1.17M | 11.66% |
| Dec 31, 2024 | 9.99M | -24.48M | -71.01% |
| Dec 31, 2023 | 34.48M | 20.63M | 148.91% |
| Dec 31, 2022 | 13.85M | 4.25M | 44.31% |
| Dec 31, 2021 | 9.60M | -2.76M | -22.35% |
| Dec 31, 2020 | 12.36M | 6.57M | 113.56% |
| Dec 31, 2019 | 5.79M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| MacroGenics | 149.50M |
| Precision BioSciences | 34.26M |
| ProQR Therapeutics | 19.19M |
| MediWound | 16.96M |
| Tonix Pharmaceuticals Holding | 13.11M |
| Korro Bio | 6.39M |
CRBU News
- 19 days ago - Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy - GlobeNewsWire
- 6 weeks ago - Caribou Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 2 months ago - Watchmaker Genomics Licenses CRISPR-Cas9 Intellectual Property from Caribou Biosciences to Increase Throughput and Reduce Sequencing Cost per Sample - Business Wire
- 2 months ago - Caribou Biosciences to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Caribou Biosciences Announces Late-Breaking Presentations at the 2026 Tandem Meetings of ASTCT® and CIBMTR® - GlobeNewsWire
- 4 months ago - Caribou Biosciences to Host In-Person and Virtual KOL Event at ASH 2025 - GlobeNewsWire
- 5 months ago - Caribou Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 5 months ago - Why Is CRISPR Genome-Editing Firm Caribou Biosciences Stock Trading Higher Today> - Benzinga